Haematologica (Oct 2020)
Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network
- Davine Hofste op Bruinink,
- Stefania Oliva,
- Lucie Rihova,
- Alexander Schmitz,
- Milena Gilestro,
- Jeroen te Marvelde,
- Romana Kralova,
- Helle Høholt,
- Annemiek Broijl,
- Hans Erik Johnsen,
- Roman Hajek,
- Mario Boccadoro,
- Pieter Sonneveld,
- Paola Omedè,
- Vincent H.J. van der Velden
Affiliations
- Davine Hofste op Bruinink
- Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands
- Stefania Oliva
- Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
- Lucie Rihova
- Department of Hematology, University Hospital Brno, Brno, Czech Republic
- Alexander Schmitz
- Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark
- Milena Gilestro
- Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
- Jeroen te Marvelde
- Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands
- Romana Kralova
- Department of Hematology, University Hospital Brno, Brno, Czech Republic
- Helle Høholt
- Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark
- Annemiek Broijl
- Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
- Hans Erik Johnsen
- Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark
- Roman Hajek
- Department of Hemato-oncology, University Hospital Ostrava and Faculty of Medicine, Ostrava University, Ostrava, Czech Republic
- Mario Boccadoro
- Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
- Pieter Sonneveld
- Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
- Paola Omedè
- Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
- Vincent H.J. van der Velden
- Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands
- DOI
- https://doi.org/10.3324/haematol.2020.267831
- Journal volume & issue
-
Vol. 106,
no. 5
Abstract
No abstracts available.
